Trial Profile
A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary hypertension
- Focus Registrational; Therapeutic Use
- Acronyms AMBER I
- Sponsors GlaxoSmithKline; GSK
- 01 Nov 2016 Status changed from completed to discontinued.
- 28 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 18 Apr 2014 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.